205. Hormone Therapy Position Statement of The North American Menopause Society

Release Date:

Here is the 2022 NAMS Hormone Therapy Position Statement!
https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
1) For women aged younger than sixty years or who are within ten years of menopause onset and have no contra indications the benefit risk ratio is favorable for treatment of bother some vasomotor symptoms and prevention of bone loss for women who initiate hormone therapy more than ten years from menopause onset.
2) We discuss safety
3) We discuss decreased mortality in women 50-60 in the WHI trial.
4) We discuss the absolute risk reduction for: all cause mortality, fracture, diabetes, and breast cancer in women aged younger than sixty years
5) Their statement on compounded and pelleted hormones
6) Vasomotor symptoms are assoicated with diminished sleep quality and reduced quality of life
7) Hormones for genitourinary syndrome of menopause
8) We discuss cognition and weight gain
9) The critical window or "healthy cell" hypothesis

Did you get the You Are Not Broken Book Yet? https://amzn.to/3p18DfK
 
Join my membership to get these episodes ASAP when they are
created and without advertisement and even listen live to the interviews and
episodes.
www.kellycaspersonmd.com/membership











---

Send in a voice message: https://podcasters.spotify.com/pod/show/kj-casperson/message

205. Hormone Therapy Position Statement of The North American Menopause Society

Title
205. Hormone Therapy Position Statement of The North American Menopause Society
Copyright
Release Date

flashback